Amicus Therapeutics, Inc. (0HF9.L)
USD 7.2
(-2.69%)
USD 7.2
(-2.69%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 198.06 Million USD | -34.7% |
| 2022 | 303.3 Million USD | 55.6% |
| 2021 | 194.93 Million USD | -30.0% |
| 2020 | 278.49 Million USD | 313.26% |
| 2019 | 67.38 Million USD | -72.15% |
| 2018 | 241.99 Million USD | 109.67% |
| 2017 | 115.41 Million USD | 454.44% |
| 2016 | -32.56 Million USD | -16.78% |
| 2015 | -27.88 Million USD | -186.75% |
| 2014 | -9.72 Million USD | 66.66% |
| 2013 | -29.16 Million USD | 12.34% |
| 2012 | -33.27 Million USD | -35.13% |
| 2011 | -24.62 Million USD | 9.59% |
| 2010 | -27.23 Million USD | -76.43% |
| 2009 | -15.43 Million USD | 42.57% |
| 2008 | -26.87 Million USD | 35.18% |
| 2007 | -41.46 Million USD | -384.26% |
| 2006 | -8.56 Million USD | -57.54% |
| 2005 | -5.43 Million USD | 0.0% |
| 2003 | - USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 234.72 Million USD | -0.0% |
| 2024 Q1 | 234.73 Million USD | 18.51% |
| 2023 Q1 | 291.41 Million USD | -3.92% |
| 2023 Q2 | 240.85 Million USD | -17.35% |
| 2023 Q3 | 190.97 Million USD | -20.71% |
| 2023 Q4 | 198.06 Million USD | 3.72% |
| 2023 FY | 198.06 Million USD | -34.7% |
| 2022 Q4 | 303.3 Million USD | 75.04% |
| 2022 Q2 | 215.4 Million USD | 0.47% |
| 2022 Q3 | 173.27 Million USD | -19.56% |
| 2022 Q1 | 214.38 Million USD | 9.98% |
| 2022 FY | 303.3 Million USD | 55.6% |
| 2021 Q3 | 53.48 Million USD | -79.83% |
| 2021 FY | 194.93 Million USD | -30.0% |
| 2021 Q2 | 265.2 Million USD | 3.53% |
| 2021 Q4 | 194.93 Million USD | 264.45% |
| 2021 Q1 | 256.15 Million USD | -8.02% |
| 2020 FY | 278.49 Million USD | 313.26% |
| 2020 Q1 | 86.53 Million USD | 28.41% |
| 2020 Q2 | 37.64 Million USD | -56.49% |
| 2020 Q3 | 229.94 Million USD | 510.82% |
| 2020 Q4 | 278.49 Million USD | 21.11% |
| 2019 Q3 | 38.98 Million USD | 219.66% |
| 2019 Q1 | 111.09 Million USD | -54.09% |
| 2019 FY | 67.38 Million USD | -72.15% |
| 2019 Q2 | -32.57 Million USD | -129.32% |
| 2019 Q4 | 67.38 Million USD | 72.87% |
| 2018 Q4 | 241.99 Million USD | 106.86% |
| 2018 Q3 | 116.98 Million USD | 21.69% |
| 2018 Q2 | 96.12 Million USD | 83.29% |
| 2018 Q1 | 52.44 Million USD | -54.56% |
| 2018 FY | 241.99 Million USD | 109.67% |
| 2017 Q1 | 112.1 Million USD | 447.3% |
| 2017 FY | 115.41 Million USD | 454.44% |
| 2017 Q4 | 115.41 Million USD | 18.37% |
| 2017 Q3 | 97.5 Million USD | -19.93% |
| 2017 Q2 | 121.77 Million USD | 8.63% |
| 2016 Q1 | 14.99 Million USD | 153.79% |
| 2016 Q3 | 32.9 Million USD | 1909.1% |
| 2016 Q4 | -32.27 Million USD | -198.09% |
| 2016 FY | -32.56 Million USD | -16.78% |
| 2016 Q2 | 1.63 Million USD | -89.08% |
| 2015 Q1 | -14.43 Million USD | -48.4% |
| 2015 Q4 | -27.88 Million USD | -191.24% |
| 2015 Q3 | 30.56 Million USD | 112.27% |
| 2015 FY | -27.88 Million USD | -186.75% |
| 2015 Q2 | -249.02 Million USD | -1625.73% |
| 2014 Q3 | -5.36 Million USD | 80.51% |
| 2014 Q4 | -9.72 Million USD | -81.11% |
| 2014 Q2 | -27.54 Million USD | -109.99% |
| 2014 FY | -9.72 Million USD | 66.66% |
| 2014 Q1 | -13.11 Million USD | 55.02% |
| 2013 Q3 | -29.64 Million USD | -29.03% |
| 2013 Q4 | -29.16 Million USD | 1.63% |
| 2013 Q1 | -26.13 Million USD | 21.44% |
| 2013 Q2 | -22.97 Million USD | 12.09% |
| 2013 FY | -29.16 Million USD | 12.34% |
| 2012 Q3 | -23.37 Million USD | 15.14% |
| 2012 Q2 | -27.54 Million USD | -20.82% |
| 2012 FY | -33.27 Million USD | -35.13% |
| 2012 Q1 | -22.79 Million USD | 7.42% |
| 2012 Q4 | -33.27 Million USD | -42.36% |
| 2011 Q2 | -24.11 Million USD | 6.08% |
| 2011 FY | -24.62 Million USD | 9.59% |
| 2011 Q4 | -24.62 Million USD | -14.78% |
| 2011 Q3 | -21.45 Million USD | 11.05% |
| 2011 Q1 | -25.67 Million USD | 5.72% |
| 2010 Q4 | -27.23 Million USD | -40.38% |
| 2010 FY | -27.23 Million USD | -76.43% |
| 2010 Q2 | -21.55 Million USD | 28.32% |
| 2010 Q3 | -19.4 Million USD | 10.0% |
| 2010 Q1 | -30.07 Million USD | -94.82% |
| 2009 FY | -15.43 Million USD | 42.57% |
| 2009 Q4 | -15.43 Million USD | 4.98% |
| 2009 Q3 | -16.24 Million USD | -24.91% |
| 2009 Q2 | -13 Million USD | 41.74% |
| 2009 Q1 | -22.32 Million USD | 16.95% |
| 2008 Q3 | -18.28 Million USD | -76.43% |
| 2008 Q1 | -15.86 Million USD | 61.74% |
| 2008 Q4 | -26.87 Million USD | -47.02% |
| 2008 Q2 | -10.36 Million USD | 34.69% |
| 2008 FY | -26.87 Million USD | 35.18% |
| 2007 FY | -41.46 Million USD | -384.26% |
| 2007 Q3 | -16.83 Million USD | 26.9% |
| 2007 Q2 | -23.03 Million USD | -38.74% |
| 2007 Q1 | -16.6 Million USD | -93.9% |
| 2007 Q4 | -41.46 Million USD | -146.26% |
| 2006 FY | -8.56 Million USD | -57.54% |
| 2006 Q4 | -8.56 Million USD | 0.0% |
| 2005 FY | -5.43 Million USD | 0.0% |
| 2005 Q4 | -5.43 Million USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| uniQure N.V. | -102.95 Million USD | 292.388% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 734.478% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -521.186% |
| bluebird bio, Inc. | 108.57 Million USD | -82.429% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 2296.817% |
| Imunon, Inc. | -4.69 Million USD | 4314.801% |
| Editas Medicine, Inc. | -87.11 Million USD | 327.358% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 98.459% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 90.559% |
| Myriad Genetics, Inc. | 88.1 Million USD | -124.818% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | -11.712% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 690.763% |
| Verastem, Inc. | -37.27 Million USD | 631.319% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 97.595% |
| Waters Corporation | 1.96 Billion USD | 89.897% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 99.262% |
| Biogen Inc. | 6.28 Billion USD | 96.85% |
| Nektar Therapeutics | 210.24 Million USD | 5.791% |
| Perrigo Company plc | 3.32 Billion USD | 94.038% |
| Dynavax Technologies Corporation | 106.63 Million USD | -85.741% |
| Illumina, Inc. | 1.21 Billion USD | 83.685% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -2742.463% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 273.912% |
| Heron Therapeutics, Inc. | 145.07 Million USD | -36.525% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -2655.879% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 47.705% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 2889.648% |
| Evolus, Inc. | 63.7 Million USD | -210.895% |
| Adicet Bio, Inc. | -142 Million USD | 239.475% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 638.162% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 830.867% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 56.82% |
| FibroGen, Inc. | 56.76 Million USD | -248.909% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 82.702% |
| OPKO Health, Inc. | 230.68 Million USD | 14.14% |
| Homology Medicines, Inc. | 18.43 Million USD | -974.28% |
| Geron Corporation | 14.76 Million USD | -1241.813% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 87.506% |
| Exelixis, Inc. | -73.05 Million USD | 371.136% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 465.056% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 231.148% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 277.793% |
| Zoetis Inc. | 4.76 Billion USD | 95.841% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 199.121% |
| Abeona Therapeutics Inc. | -10.07 Million USD | 2066.687% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 102.071% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 1459.216% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 81.213% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 79.547% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 246.281% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 85.657% |
| Blueprint Medicines Corporation | 702.83 Million USD | 71.819% |
| Insmed Incorporated | 721.62 Million USD | 72.553% |
| TG Therapeutics, Inc. | 17.86 Million USD | -1008.862% |
| Incyte Corporation | -3.17 Billion USD | 106.238% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 74.136% |